Quant Healthcare Fund
The scheme seeks to long term capital appreciation by investing in equity/equity related instruments of companies from the healthcare sector. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.
Growthvine rating: 3/5 — ranked #23 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹18.36 (as of 2026-11-13) |
|---|
| AUM | ₹425 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ayusha Kumbhat |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| Sharpe ratio | 0.76 |
|---|
| Standard deviation | 18.16% |
|---|
| Max drawdown | −25.79% |
|---|
| Alpha | -2.52 |
|---|
| Beta | 0.98 |
|---|
Over 5 years, captured 84.1% of NIFTY Pharma's upside and 76.0% of its downside.
Market cap allocation
| Large cap | 0.0% |
|---|
| Mid cap | 65.4% |
|---|
| Small cap | 34.6% |
|---|
Concentration
| Top 5 holdings | 48.3% |
|---|
| Top 10 holdings | 83.1% |
|---|
| Total holdings | 16 |
|---|
Top holdings
- TREPS — 21.1%
- Zydus Lifesciences Limited — 10.3%
- Divis Laboratories Ltd. — 9.9%
- Aurobindo Pharma Ltd. — 9.8%
- Glenmark Pharmaceuticals Ltd. — 9.4%
- GlaxoSmithkline Pharmaceuticals Ltd. — 8.9%
- STRIDES PHARMA SCIENCE LIMITED — 8.8%
- Torrent Pharmaceuticals Ltd. — 8.5%
- Pfizer Ltd. — 7.1%
- Ipca Laboratories Ltd. — 5.4%
Top sectors
- Pharma & Biotech — 55.2%
- Derivatives — 32.8%
- SOV — 6.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 22.7% | Q1 (Top) | #9 of 76 |
| 2025 | −5.2% | Q4 (Bottom) | #57 of 69 |
| 2024 | 29.7% | Q2 | #23 of 58 |